Emerging HER2-targeted ADCs: How do they differ from T-DM1?
Dr Judy King talks us through the structure of antibody-drug conjugate (ADC)s and how novel ADCs are utilising both the classical ADC mechanism of action and the bystander killing effect. She also briefly reviews novel human epidermal growth factor receptor (HER)2-targeted ADCs either recently approved or in development for the treatment of breast cancer and highlights how these therapies may provide additional treatment options for patients.view bio and disclosures 1/3 Next Chapter
New ADCs and new targets: Looking to the future for advanced HER2+ and HER2-low breast cancer
Dr Judy King walks us through the latest data on the use of HER2-targeted ADCs in the treatment of HER2-low advanced breast cancer and reviews the development of novel therapeutics targeting HER3.view bio and disclosures 3/3 Take CME Test
Overview & Learning Objectives
In this activity, Dr Judy King, an expert in breast cancer, discusses the emerging human epidermal growth factor receptor (HER)-targeted antibody-drug conjugates (ADCs) in development for the treatment of breast cancer, and how these therapies may change clinical practice.
This activity has been jointly provided by Oakstone and touchONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
This activity has been designed to meet the needs of oncologists, nurses and other healthcare professionals involved in the management of patients with breast cancer.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Dr Judy King discloses: Advisory board/consultancy fees from Eisai, Eli Lilly and Company, Genomic Health, Novartis, Pfizer Inc. and Roche.
Walter Murray Yarbrough, MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Alison Scott has no financial interests/relationships or affiliations in relation to this activity.
Requirements for successful completion
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AME). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Date of original release: July 08, 2020. Date credits expire: July 08, 2021.
After watching this activity participants should be better able to:
- Describe how the structure and mechanism of action of antibody-drug conjugates may address current unmet treatment needs in patients with advanced breast cancer
- Evaluate clinical data for emerging anti-HER2 antibody-drug conjugates used to treat patients with HER2-positive advanced breast cancer
- Discuss how clinical practice may change with the emergence of novel HER-targeted antibody-drug conjugates for patients with advanced breast cancer
Faculty & Disclosures
Dr Judy King
Royal Free London NHS Foundation Trust, London, UK
Judy King is a consultant medical oncologist at the Royal Free London NHS Foundation Trust in the UK. She qualified from Cambridge University and Guys and St Thomas’ School of Medicine and Dentistry in 2001 and completed a PhD in T cell immunotherapy of malignancies in 2008. During her specialty training, she also completed a Darzi Fellowship in Leadership and Management and completed a Postgraduate Certificate from Leeds Business School.
Disclosures: Advisory board/consultancy fees from Eisai, Eli Lilly and Company, Genomic Health, Novartis, Pfizer Inc. and Roche.